jynt-20250408

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934


☒						Filed by the Registrant
☐						Filed by a Party other than the Registrant

Check the appropriate box:


☐			Preliminary Proxy Statement
☐			Fee paid previously with preliminary materials.Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒			Definitive Proxy Statement
☐			Definitive Additional Materials
☐			Soliciting Material under Rule 14a-12

THE JOINT CORP.

(Name of registrant as specified in its charter)

(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check all boxes that apply):


☒			No fee required.
☐			Fee paid previously with preliminary materials.
☐			Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Dear Fellow Stockholders:

The Joint provides access to many with affordable, concierge-style, membership-based services in convenient retail settings. I joined the company in October 2024, because The Joint is a highly differentiated scale player with a strong core and significant opportunities. My goal is to activate our talented leadership team to leverage our advantages to become a world class, pure play franchisor. We are implementing initiatives to improve our clinic economics and company profitability, increase clinic count, and create stockholder value. Before I unveil our new strategic plan, let’s review our financial and operating highlights for 2024, compared to 2023.

2024 Performance Highlights

Our financial and operating highlights for 2024, compared to 2023 were as follows:

14.7 million

PATIENT VISITS, UP FROM 13.6 MILLION

1.9 million

UNIQUE PATIENTS, UP FROM 1.7 MILLION

957,000

NEW PATIENTS, UP FROM 932,000

36%

OF NEW PATIENTS HAD NEVER VISITED A CHIROPRACTOR BEFORE THE JOINT, CONSISTENT WITH THE PRIOR YEAR

85%

OF SYSTEM-WIDE GROSS SALES FROM MEMBERSHIPS, ALSO CONSISTENT WITH THE PRIOR YEAR

10%

INCREASE IN REVENUE FROM CONTINUING OPERATIONS TO $51.9 MILLION FROM $47.0 MILLION1

INCREASE IN SYSTEM-WIDE SALES2 GREW TO $530.3 MILLION

$1.5 million

NET LOSS FROM CONTINUING OPERATIONS, COMPARED TO $10.8 MILLION NET LOSS FROM CONTINUING OPERATIONS

$2.7 million

IN ADJUSTED EBITDA FROM CONTINUING OPERATIONS, COMPARED TO $4.5 MILLION

1.At year-end, we recorded the corporate-owned or managed clinics as discontinued operation for 2024 and recast 2023 for an apples-to-apples comparison. In 2024, this recognition eliminated the $70.2 million in associated revenue, $66.5 million in associated SG&A, and $10.4 million in associated impairment and a net loss for discontinued operations of $7.0 million.

2.System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.

In addition, The Joint is frequently recognized for our excellence. For instance, in 2024, SUCCESS named us as one of the “Top 50 Franchises” and Franchise Times recognized The Joint as No. 38 on the Fast & Serious and ranked No. 150 of annual “Top 400.” In addition, in early 2025, Entrepreneur Magazine’s named The Joint the top franchise in chiropractic services and No. 54 on Franchise 500, jumping 29 spots since last year.

While we continued to improve KPIs and grow the business and we are proud of our accolades, I see areas for improvement to strengthen our position as the leading chiropractic care provider, become a pure play franchisor, grow sales, reduce overhead and improve profitability.

Focused on Becoming a World Class, Pure Play Franchisor

My team and I performed an extensive 100 days analysis of The Joint, the chiropractic care and adjacent industries yielding actionable data. Each of our strategic priorities fosters the next, creating a flywheel. After placing patients at the heart of everything we do, we have begun to do the following:

•Build our people capability and culture to support our clinics, nurture talent, strengthen engagement, and attract and retain the best Doctors of Chiropractic. This will enable us to

•Excel in patient experience. By optimizing care delivery and patient touchpoints, we will fuel our most effective and cost-efficient patient acquisition tool – referrals – as well as

•Turbo charge sales and profits for both our franchisees and the company. By bolstering our foundation, refranchising and reducing unallocated overhead expenses, we will improve the bottom line, which will

•Reignite clinic network growth. By updating our key development processes to ensure stronger new clinic performance, we will drive sustainable new clinic growth in the large white space we have. Simultaneously, we will also

•Innovate and broaden our relevance. We will refresh our brand communications and brand architecture, start to re-platform the tech stack and explore new chargeable options for patient clinical care.

These key priorities set the foundation of our strategic growth plan.

Unveiling The Joint’s Multi-year Phased Approach for Growth

In our next phase, or The Joint 2.0, we will strengthen our core, reignite growth, and improve clinic and company level profitability. As we refranchise our corporate clinics and shift to a pure franchise concept, The Joint as a company will benefit economically. We will no longer carry the costs of operating clinics, reducing overhead and increasing operating leverage. Refranchising will increase our capital. We will evaluate measures to improve our profitability profile, like acquiring regional developer territories, and/or return value to stockholders, like a stock repurchase program.

To drive revenue growth, we will initiate dynamic revenue management, strengthen our digital marketing and promotional calendar, and upgrade our patient facing technology. In addition, we will begin building infrastructure, test and validate elements of other revenue drivers that will shape our next phase.

In The Joint 3.0, we will capture new revenue streams by creating additional sales channels and growing in new markets. We will evaluate various alternatives, including:

•Expanding into systemwide enterprise or business accounts, building a B2B business to complement our B2C business;

•Building a tech differentiated competitive moat;

•Unlocking dense urban markets;

•Monetizing new clinical service(s) and chiropractic usage occasions; and

•Exploring opportunities to sell retail products in our clinics.

Our new strategic plan to strengthen our core and reignite our growth leverages our advantages to capture opportunities.

The Joint’s Advantages Create Opportunity

The Joint’s attractive asset-light, recurring revenue model attracts franchisees. In 2024, 85% of our revenue was contributed by memberships. Regarding clinic, or storefront, buildouts, The Joint has one of the lowest initial costs among health and wellness concepts, compared to Pilates studios, saunas, gyms and so on. At the end of December 31, 2024, we had over 960 clinics, making The Joint larger than our next 10 competitors combined and the clear category leader. This scale, combined with our first mover advantage and premier nationwide brand, has increased brand awareness and easy consumer access. Yet we have only scratched the surface and significant market opportunity remains available for growth. In the US alone, based on our current programming, when we conduct a bottom-up analysis, we have identified ideal locations with complementary demographics for approximately another 1,000 clinics – basically, we are only 50% of the way there. And when we review from the top down, we know the annual spending on chiropractic care is estimated to be $20.6 billion annually with out-of-pocket spend ranging from 37% to 42% of that total. As The Joint’s 2024 gross system sales of $530.5 million, representing between 6% and 7% of that out-of-pocket spend. And now, in 2025, we have a new detailed strategic plan to strengthen our core and reignite growth. We are committed to driving success, which we will define as growth in net new clinic openings, system-wide sales, comp sales and Adjusted EBITDA.

Emphasizing our Commitment to Patients and Stakeholders

Stockholders, we realize you have a lot of choices when choosing where to invest. We appreciate your trust in The Joint.

As noted earlier, we have placed patients at the heart of everything we do, which aligns perfectly with The Joint’s mission to improve the quality of life through routine and affordable chiropractic care. Upon evaluating our solid foundation and numerous opportunities, my team and I are augmenting The Joint’s vision: To become America's most accessible health and wellness services company.

This proxy statement and accompanying materials are first being made available to stockholders on or about April 8, 2025. The proxy materials include instructions on how to vote online, by phone, and by mail. Your vote is important regardless of the number of shares you own. Whether or not you plan to attend the 2025 Annual Meeting, we encourage you to consider the matters presented in the proxy statement and vote as soon as possible. We hope that you will be able to join us on May 21st. Thank you for your ownership and support of The Joint Corp.

Sanjiv Razdan

President and Chief Executive Officer

2024 Financial Highlights

For 2024, The Joint reached another record level for system-wide sales, delivered steady annual same-store sales growth, and generated $9.4 million of cash from operations. These achievements reflect the company business model’s resiliency and the validation of future opportunities and growth.

•Opened 32 new clinics, net of closures, bringing total to 967

•Increased system-wide sales to$530.3 million, up 9% compared to 2023

•Increased number of unique patients treated to 1.9 million, up from 1.7 million in 2023

•Sold 57 franchise licenses, compared to 55 in 2023

•Expanded franchise clinic portfolio by 42, net of closures, bringing the total to 842

•Delivered cash flow from operations of$9.4 million


967 locations IN 41 STATES
14.7 million PATIENT ADJUSTMENTS IN 2024
$530 million SYSTEM-WIDE4 GROSS SALES
9% increase ANNUAL SYSTEM-WIDE4 GROSS SALES INCREASE
4% ANNUAL COMP SALES3 FOR CLINICS >13 MONTHS
(2)% ANNUAL COMP SALES3 FOR CLINICS >48 MONTHS
57 FRANCHISE LICENSES SOLD IN 2024
85% OF REVENUE FROM RECURRING MEMBERSHIPS

The Joint Corp. 14-yr. CAGR 54%1 vs. Industry 5-yr. CAGR 5.1%2

1.For the period ended December 31, 2024

2.June 2023 Kentley Insights Chiropractic Care Market Research Report

3.Comp sales refers to the revenues a clinic generates in the most recent accounting period, compared to revenues in the comparable period of the prior year, and (i) includes revenues only from clinics that have been open at least 13 full months and (ii) excludes any clinics that have closed.

4.System-wide sales include revenues generated by all clinics, whether operated by the company or by franchisees. While franchise sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.


			16767 N. Perimeter Drive, Suite 110 Scottsdale, AZ 85260

To Our Stockholders

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

Date:

Wednesday, May 21, 2025

Time:

9:00 a.m. Mountain Standard Time

Place:

Virtual Internet

Our 2025 annual meeting of stockholders (the “2025 Annual Meeting”) will be held on Wednesday, May 21, 2025 at 9:00 a.m. Mountain Standard Time.

At the 2025 Annual Meeting, you will be asked to consider and vote on the following items:

election to the Board of Directors of the seven nominees for director named in this proxy statement;

approval, on an advisory basis, of the compensation of our named executive officers;

ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2025; and

any other matter that properly comes before the meeting.

YOUR VOTE IS IMPORTANT

These items of business are more fully described in the proxy statement accompanying this notice.

Only stockholders of record at the close of business on the record date of March 24, 2025 are entitled to vote at the 2025 Annual Meeting. If you need directions to the 2025 Annual Meeting, please call Investor Relations at (480) 245-5960.

If you have previously given your proxy and later decide to attend the 2025 Annual Meeting in person, or if for any other reason you want to revoke your proxy, you may do so at any time before your proxy is voted. If you hold your shares through a broker, bank, or other nominee, please see the instructions in the General Information section on how to vote your shares, either by written instruction or in person at the 2025 Annual Meeting. Please carefully read the enclosed information and our annual report, which includes our Annual Report on Form 10-K for the year ended December 31, 2024, before voting your proxy. This proxy statement and our annual report are available for your review at https://www.proxyvote.com.

This proxy statement and accompanying materials are first being made available to stockholders on or about April 8, 2025.

By Order of the Board of Directors,

Jake Singleton

Chief Financial Officer

Scottsdale, Arizona

April 8, 2025

Whether or not you plan on attending the 2025 Annual Meeting, we ask that you vote by proxy by following instructions provided in the Notice of Internet Availability of Proxy Materials or, if you receive paper copies of the proxy materials by mail, as provided in the enclosed proxy card as promptly as possible.

Table of Contents


PROXY SUMMARY INFORMATION			1
PROXY STATEMENT			3
Explanatory Note			3
Security Ownership of Certain Beneficial Owners And Management			3
PROPOSAL 1 – ELECTION OF DIRECTORS			6
Voting in Uncontested Director Election			6
Nominees for Director			7
Director Skills and Qualifications			15
CORPORATE GOVERNANCE			16
Director Independence			16
Leadership Structure of the Board of Directors			16
Committees of the Board of Directors			16
Compensation Committee			16
Audit Committee			17
Nominating and Governance Committee			18
Committee Charters			20
Committee Members and Meetings			20
Director Compensation			21
Executive Sessions of the Board of Directors			22
Board of Directors’ Evaluation			22
Required Resignation on Change of Job Responsibilities			22
Communications with the Board of Directors			22
Policies and Procedures for Related Person Transactions			22
Related Person Transactions			23
Anti-Hedging Policy			23
Code of Business Conduct and Ethics			24
Risk Oversight			24
Stock Ownership Guidelines			25


AUDIT COMMITTEE REPORT			26
Executive Officers			27
EXECUTIVE COMPENSATION			28
Summary Compensation Table			28
Pay versus Performance Table			29
Employment Agreements and Change in Control Arrangements			33
Clawback Policy			35
Outstanding Equity Awards at Fiscal Year-End			36
Policies and Practices Related to the Grant of Certain Equity Awards			38
Equity Compensation Plan Information			39
Delinquent Section 16(a) Reports			39
PROPOSAL 2 – ADVISORY VOTE ON EXECUTIVE COMPENSATION			40
PROPOSAL 3 – RATIFICATION OF APPOINTMENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM			42
Audit Fees			42
Audit-Related Fees			42
Tax Fees			42
All Other Fees			42
GENERAL INFORMATION			43
ANNUAL REPORT			47
HOUSEHOLDING OF PROXY MATERIALS			47
OTHER MATTERS			47
STOCKHOLDER PROPOSALS AND NOMINATIONS FOR THE 2026 ANNUAL MEETING (WITH DEADLINES)			48


Agenda Item	Board Recommendation	Page


Election to the Board of Directors of the seven nominees for director named in this proxy statement	FOR EACH NOMINEE	6


Approval, on an advisory basis, of the compensation of our named executive officers	FOR	40


Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2025	FOR	42


Executive Officers and Directors	Number of Shares Beneficially Owned	Percentage of Shares

Matthew E. Rubel	12,468	*
Ronald V. DaVella	12,534	*
Suzanne M. Decker	31,098	*
Jefferson Gramm(1)	3,937,296	25.7%
Peter D. Holt	177,978	1.2%
Abraham Hong	21,148	*
Glenn J. Krevlin	29,475	*
Sanjiv Razdan	89,032	*
Jake Singleton(2)	171,804	1.1%
Executive officers and directors as a group (8 persons)(2)	4,304,855	27.9%
Beneficial holders of 5% or more of our outstanding common stock

Bandera Partners LLC(1)	3,937,296	25.7%
The Vanguard Group Inc.(3)	1,031,068	6.7%
BlackRock Fund, Inc.(4)	829,833	5.4%


VOTE

The Board of Directors recommends that stockholders vote “FOR” each of the seven nominees to the Board of Directors.


Nominee	Position with our Company	Age

Matthew E. Rubel	Lead Director	67
Ronald V. DaVella	Director	67
Suzanne M. Decker	Director	63
Jefferson Gramm	Director	49
Christopher M. Grandpre	None	58
Abraham Hong	Director	53

Sanjiv Razdan	President, Chief Executive Officer and Director	55


			Senior Management Leadership Experience serving in a senior leadership role of a major organization ( e.g. CFO, General Counsel, President, or Division Head)
			Franchise & Industry Expertise Franchising expertise or experience in health or retail related industries
			Public Company Board Service Experience as a board member of another publicly-traded company
			Operations Management Expertise Experience or expertise in managing the operations of a business or major organization
			Financial Acumen & Expertise Experience or expertise in financial accounting and reporting or the financial management of a major organization
			IT and/or Risk Management Expertise Experience in or knowledge of information technology or risk oversight, or the development of IT and risk management policy and procedures
			Corporate Finance and M&A Expertise Experience in corporate lending or borrowing, capital markets transactions, significant mergers or acquisitions, private equity, or investment banking
			Marketing or Branding Expertise Experience in or knowledge of brand development, consumer insight, or market research
			CEO Leadership Experience serving as the Chief Executive Officer of a major organization
			Real Estate Expertise Experience in or knowledge of retail or commercial real estate


Audit Committee(1)			Position

Ronald V. DaVella			p
Abraham Hong			l
Glenn J. Krevlin(2)			l
Compensation Committee			Position

Suzanne M. Decker			p
Jefferson Gramm			l
Abraham Hong			l
Nominating And Governance Committee			Position

Glenn J. Krevlin(2)			p
Ronald V. DaVella			l
Matthew E. Rubel Lead Director			l


Name	Fees Earned or Paid in Cash ($)	Stock Awards(1)(2) ($)	Option Awards ($)	Non-Equity Incentive Pl Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)

Matthew E. Rubel	71,000	50,000	—	—	—	—	121,000
Ronald V. DaVella	74,000	50,000	—	—	—	—	124,000
Suzanne M. Decker	58,000	50,000	—	—	—	—	108,000
Jefferson Gramm	—	—	—	—	—	—	—
Abraham Hong	59,000	50,000	—	—	—	—	109,000
Glenn J. Krevlin(3)	68,000	50,000	—	—	—	—	118,000


Category			Stock Ownership Target

CEO			3 times annual total cash compensation
Other §16 Officers			2 times annual total cash compensation
Board of Directors			2 times annual cash retainer


Executive Officer	Position with our Company	Age

Sanjiv Razdan	President, Chief Executive Officer and Director	55
Jake Singleton	Chief Financial Officer	43


Name	Year	Salary ($)	Bonus ($)	Stock Awards(1) ($)	Option Awards(1) ($)	Non-Equity Incentive Plan Compensation(3) ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation(2) ($)	Total ($)

Sanjiv Razdan(4) President and Chief Executive Officer	2024	127,703	100,000	400,000	236,532	—	—	—	864,235
	2023	—	—	—	—	—	—	—	—
	2022	—	—	—	—	—	—	—	—
Peter D. Holt(5) Former President and Chief Executive Officer	2024	398,547	—	271,822	—	—	—	524,424	1,194,793
	2023	418,200	—	271,811	—	—	—	16,085	706,096
	2022	453,446	—	271,830	—	—	—	16,085	741,361
Jake Singleton Chief Financial Officer	2024	330,266	—	245,688	—	83,475	—	13,211	672,640
	2023	311,298	—	217,611	—	—	—	12,452	541,361
	2022	270,679	—	124,968	—	—	—	10,242	406,418


Year	Summary Compensation Table Total for First PEO(1) ($)	Summary Compensation Table Total for Second PEO(1) ($)	Compensation Actually Paid to First PEO(3) ($)	Compensation Actually Paid to Second PEO(4) ($)	Summary Compensation Table Total for non-PEO named executive officers(1) ($)	Compensation Actually Paid to non-PEO named executive officers(5) ($)	Value of initial fixed $100 investment based on Total Shareholder Return ($)	Net Income/(Loss) ($)	EBITDA(2) ($)

2024	1,194,793	864,235	759,315	881,867	672,640	750,547	(79)	(8,529,843)	(3,811,095)
2023	706,096	N/A	561,371	N/A	541,361	440,384	(85)	(9,752,197)	10,288,420
2022	741,361	N/A	(1,727,094)	N/A	406,418	(820,580)	(84)	626,705	7,474,876


Adjustments to Determine Compensation to First PEO	2024	2023	2022

Deduction for amounts reported under “Stock Awards” column in SCT	$(271,822)	$(271,811)	$(271,830)
Deduction for amounts reported under “Option Awards” column in the SCT	—	—	—
Increase for fair value of awards granted during year that remain unvested during that year	—	166,311	92,687
Increase for fair value of awards granted during year that vest during that year	—	—	—
Increase/(deduction) for change in fair value from prior year-end to current year-end of awards granted prior to year that were outstanding and unvested as of year-end	—	(61,052)	(1,451,457)
Increase/(deduction) for change in fair value from prior year-end to vesting date of awards granted prior to year that vested during year	(2,405)	21,827	(837,855)
Deduction of fair value of awards granted prior to year that were forfeited during year	(161,251)	—	—
Increase based upon incremental fair value of awards modified during year	—	—	—
Increase based on dividends or other earnings paid during year prior to vesting date of awards	—	—	—
TOTAL ADJUSTMENTS	$(435,478)	$(144,725)	$(2,468,455)


	Option Awards(1)					Stock Awards(2)
Name	Number of securities underlying unexercised options exercisable ($)	Number of securities underlying unexercised options unexercisable ($)	Option exercise price ($)	Option grant date	Option expiration date	Number of shares of stock that have not vested ($)	Market value of shares that have not vested ($)

Sanjiv Razdan	0	38,059 (3)	10.51	10/14/2024	10/14/2034







	—	—	—		—	38,059(4)	404,567
Peter D. Holt(5)	34,718	— (6)	12.02	3/5/2019	3/5/2029
	21,992	— (7)	14.68	3/3/2020	3/3/2030
	6,245	— (8)	45.39	3/2/2021	3/2/2031
	—	—	—	—	—	—	—
Jake Singleton	10,000	— (9)	4.10	3/14/2016	3/14/2026
	20,000	— (10)	2.24	8/9/2016	8/9/2026
	10,473	— (11)	3.88	5/9/2017	5/9/2027
	10,000	— (12)	5.51	11/10/2017	11/10/2027
	3,242	— (13)	8.25	8/7/2018	8/7/2028
	35,000	— (14)	7.10	11/6/2018	11/6/2028
	10,057	— (15)	14.68	3/3/2020	3/3/2030
	2,856	952 (16)	45.39	3/2/2021	3/2/2031
	—	—	—	—	—	35,396(17)	376,259


Plan Category	Number of securities to be issued upon exercise of options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights(1)	Number of securities remaining available for future issuance under equity compensation plans (excluding securities in column (a))

	(a)	(b)	(c)

Equity compensation plans approved by security holders	243,918	$12.00	1,941,090
Equity compensation plans not approved by security holders	38,059	$10.51	—
Total	281,977	$22.51	1,941,090


1			Attract and retain highly qualified and productive executives;
2			Motivate executives to enhance our overall performance and profitability through the successful execution of our short-term and long-term business strategies, with an emphasis on the long term;
3			Align the long-term interests of our executives and stockholders through ownership of our common stock by executives and by rewarding stockholder value creation; and
4			Ensure that compensation opportunities are competitive.


FOR			each of the seven nominees for election to the Board of Directors (Proposal 1);
FOR			approval, on an advisory basis, of the compensation of our named executive officers (Proposal 2); and
FOR			ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2025 (Proposal 3).


Proposal 1	you may vote “For” or “Against”	each individual nominee for election to the Board of Directors or “Abstain” from voting on the nominee’s election.
Proposal 2	you may vote “For” or “Against”	approval, on an advisory basis, of the compensation of our named executive officers or “Abstain” from voting.
Proposal 3	you may vote “For” or “Against”	ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2025 or “Abstain” from voting.


Proposal 1 (election to the Board of Directors of the seven nominees for director named in this proxy statement):			Each nominee for election to the Board of Directors must receive more “For” votes than “Against” votes in order to be elected as a director. Abstentions and broker non-votes will not be included in the vote tally and will not have any effect on the voting.
Proposal 2 (vote, on an advisory basis, of the named executive officer compensation):			This proposal requires for approval the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote. Abstentions will have the same effect as a vote “Against.” Brokers do not have discretionary authority to vote on this proposal. Broker non-votes, therefore, will have no effect on the proposal as brokers are not entitled to vote on such proposals in the absence of voting instructions from the beneficial owner.
Proposal 3 (ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2025):			This proposal requires for approval the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote. Abstentions will have the same effect as a vote “Against.” Brokers will have discretionary authority to vote Proposal 3, and therefore there will not be any broker non-votes on this matter.


			Time and Date Wednesday, May 21, 2025, at 9:00 a.m.. Mountain Standard Time						Place 16767 N. Perimeter Drive, Suite 110, Scottsdale, Arizona 85260

SEC Form DEF 14A filed by The Joint Corp.